CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos


ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s


CRT 23: PCI Vs CABG in Left Main CAD With or Without Diabetes

Prakriti Gaba,

Watch time: 4m 19s

Video Series

The Changing Face of Lipid Management in the UK

Kausik Ray, , , et al

Watch time: 95m (4 videos)


Radcliffe & CardioNerds @AHA22: The PROMINENT Trial

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
Women and Diabetes: Preventing Heart Disease in a New Era of Therapies

European Cardiology Review 2021;16:e40.

Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes

European Cardiology Review 2021;16:e14.

Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know

European Cardiology Review 2021;16:e12.

A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease

European Cardiology Review 2021;16:e11.

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease

European Cardiology Review 2020;15:e04.

Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis

European Cardiology Review 2020;15:e40.

Protocol of a Randomised, Single Blind, Placebo-controlled RESCAP Intervention Study to Determine the Safety of RESCAP in Diabetes: RAPID Protocol – Rationale and Design

European Cardiology Review 2020;15:e41.

Statins and Insulin Resistance

European Cardiology Review 2020;15:e44.

The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives

European Cardiology Review 2019;14(1):50–9


European Cardiology Review 2019;14(1):5

Characteristics of Lipid Profile of LPL Deficiency in Japan – Comparison with Non-LPL Deficiency

European Cardiology Review 2018;13(2):132.

ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

European Cardiology Review 2018;13(1):21–2.

Neuroendocrine System Regulatory Mechanisms: Acute Coronary Syndrome and Stress Hyperglycaemia

European Cardiology Review 2018;13(1):29–34.

Featuring: Prof Carlo Patrono

European Cardiology Review 2017;12(1):63–6

Diabetes Management – Lowering Cardiovascular Risk

European Cardiology Review 2014;9(1):7–9

Foreword - European Cardiology Review – New Beginnings

European Cardiology Review 2014;9(1):6

Statins: Practical Considerations – A Review

European Cardiology Review 2014;9(2):71–5

Angiotensin-receptor Blocker Therapy - Chronic Kidney Disease and Diabetes

European Cardiovascular Disease 2006;2(2):1–5


European Cardiology 2010;6(1):8

Microvascular Complications and Outcome after Drug-eluting Stent Implantation in Diabetic Patients

European Cardiovascular Disease 2007;3(1):95–6